Inclusion Criteria:  Males & females ≥ 18 years age. Established ASCVD On maximally tolerated lipid-modifying therapy Fasting LDL-C ≥ 80 mg/dL Fasting triglycerides < 400 mg/dL Estimated glomerular filtration rate ≥ 30 mL/min  Exclusion Criteria:  New York Heart Association class III or IV heart failure or left ventricular ejection fraction < 30% Have been hospitalized for Heart Failure within 5 years prior to screening Had non-fatal MI, non-fatal stroke, non-elective coronary revascularization and/or hospitalization for unstable angina or chest pain within past 3 months prior to screening Uncontrolled hypertension Diagnosis of homozygous familial hypercholesterolemia (HoFH) Active liver disease HbA1c ≥10% Thyroid Stimulating Hormone (TSH) > 1.5 times upper limit normal Creatine kinase > 3 times upper limit normal History of malignancy with surgery in past 3 years History of alcohol or drug abuse within past 5 years Received treatment with investigational product or device within past 30 days excluding Coronavirus treatment or vaccine Known allergy to study drug Participated in previous obicetrapib trial